Greenleaf Peter 4

What Happened Peter Greenleaf, a director of Pelthos Therapeutics (PTHS), reported the sale of a total of 797 shares of common stock in open-market transactions on July 2, 2026. The sales consisted of 712 shares at a weighted-average price of $26.00 (total ≈ $18,509) and 85 shares at a weighted-average price of $27.27 (total ≈ $2,318), for aggregate proceeds of about $20,827. These were sales (not purchases) and therefore generally reflect disposition of shares rather than a direct bullish signal.

Key Details

• Transaction date: July 2, 2026 (reported on Form 4 filed July 7, 2026).
• Prices and sizes:
  • 712 shares sold — weighted-average $26.00 (prices ranged $25.58–$26.53).
  • 85 shares sold — weighted-average $27.27 (prices ranged $27.20–$27.63).
• Total shares sold: 797; total proceeds ≈ $20,827.
• Shares owned after transaction: Not specified in the excerpt provided.
• Notable footnotes:
  • The sales were made pursuant to a Rule 10b5‑1 trading plan adopted December 16, 2025 to satisfy estimated tax obligations tied to RSU vesting. (Footnote F1)
  • Footnotes F2 and F3 note these sales were executed in multiple trades; the prices shown are weighted averages and the reporting person can provide full trade-price details on request.
• Filing timing: Trade date 7/2/2026; Form 4 filed 7/7/2026 (5 calendar days later). Typical Form 4 reporting deadline is within two business days of the transaction.

Context

• These sales were done under a pre-established Rule 10b5‑1 plan and are described as being for tax-withholding/estimated tax purposes in connection with RSU vesting — a common reason insiders sell shares and not necessarily an indicator of a change in view on the company.
• For retail investors, purchases by insiders tend to be more informative about confidence; routine, plan-driven sales like this are more often administrative.